rofecoxib has been researched along with Hemophilia A in 5 studies
Hemophilia A: The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The most common adverse experiences were upper respiratory infection and headache." | 2.72 | Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy. ( Curtis, SP; Eyster, ME; Giallella, KM; Melian, A; Mukhopadhyay, S; Reicin, AS; Shingo, S; Tsoukas, C, 2006) |
| "Rofecoxib was used for eight acute haemarthrosis, four target joints, seven cases of synovitis and 12 episodes of pain." | 1.33 | Rofecoxib as adjunctive therapy for haemophilic arthropathy. ( Nugent, DJ; Rattray, B; Young, G, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, TT | 1 |
| Solomon, DH | 1 |
| Kesselheim, AS | 1 |
| Ross, JS | 1 |
| Krumholz, HM | 1 |
| Bragadóttir, G | 1 |
| Onundarson, PT | 1 |
| Rattray, B | 1 |
| Nugent, DJ | 1 |
| Young, G | 1 |
| Tsoukas, C | 1 |
| Eyster, ME | 1 |
| Shingo, S | 1 |
| Mukhopadhyay, S | 1 |
| Giallella, KM | 1 |
| Curtis, SP | 1 |
| Reicin, AS | 1 |
| Melian, A | 1 |
1 trial available for rofecoxib and Hemophilia A
| Article | Year |
|---|---|
Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy.
Topics: Adolescent; Adult; Aged; Child; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Double-Blind Method; | 2006 |
4 other studies available for rofecoxib and Hemophilia A
| Article | Year |
|---|---|
Fool Me Twice? The Reemergence of Rofecoxib and the Orphan Drug Act.
Topics: Arthritis; Cardiovascular Diseases; Chronic Pain; Hemophilia A; Humans; Lactones; Orphan Drug Produc | 2019 |
Bringing Vioxx back to market.
Topics: Arthralgia; Drug Approval; Hemophilia A; Humans; Lactones; Safety-Based Drug Withdrawals; Sulfones | 2018 |
Factor-sparing use of the COX-2 inhibitor rofecoxib in haemophilic arthropathy.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclo | 2002 |
Rofecoxib as adjunctive therapy for haemophilic arthropathy.
Topics: Acute Disease; Adjuvants, Pharmaceutic; Administration, Oral; Adolescent; Adult; Anti-Inflammatory A | 2005 |